Physician profile
Obaeda Harfoush
NPI 1386809184
$1,152.82
in general payments reported to CMS, 2019-2025
23 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $213 · 2020: $56.22 · 2021: $145 · 2022: $290 · 2023: $291 · 2024: $159.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $449.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $449.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $182.80 | 2019-2023 | Trelegy Ellipta, Nucala, Arexvy |
| Pulmonx Corporation | $161.83 | 2022-2024 | Zephyr Delivery Catheter, Pulmonx Chartis Tablet Console, Chartis Catheter |
| Novartis Pharmaceuticals Corporation | $89.94 | 2019-2023 | |
| Insmed, INC. | $88.67 | 2019-2021 | |
| Genentech USA, INC. | $70.72 | 2019 | |
| La Jolla Pharmaceutical Company | $63.41 | 2021-2022 | |
| Grifols USA, LLC | $55.51 | 2021-2024 | Prolastin-C Liquid |
| Sunovion Pharmaceuticals INC. | $54.21 | 2019-2020 | |
| Astrazeneca Pharmaceuticals Lp | $45.94 | 2019-2024 | Fasenra |
| Abbvie INC. | $42.60 | 2022-2023 | |
| Tetraphase Pharmaceuticals, INC. | $36.02 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $35.28 | 2022-2024 | Glassia |
| Merck Sharp & Dohme LLC | $27.56 | 2024 | Recarbrio, Zerbaxa, Dificid |
| Shionogi INC | $25.47 | 2022 | |
| Janssen Pharmaceuticals, INC | $25.34 | 2021-2022 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $23.74 | 2023 | Illumisite |
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.18 | 2022 | |
| Resmed Corp | $19.86 | 2023 | |
| Teva Pharmaceuticals USA, INC. | $19.14 | 2022 | |
| United Therapeutics Corporation | $19.13 | 2022 | |
| Amgen INC. | $16.22 | 2023 | Tezspire |
| Olympus America INC. | $14.17 | 2020 | |
| Jazz Pharmaceuticals INC. | $14.08 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Obaeda Harfoush listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.